Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.

Journal of cardiovascular translational research - 1 Jun 2017

Shah Sanjiv J

Abstract excerpt

A major challenge in the care of patients with heart failure and preserved ejection fraction (HFpEF) is the lack of proven therapies due to disappointing results from randomized controlled trials (RCTs). The heterogeneity of the HFpEF syndrome and the use of conventional RCT designs are possible reasons underlying the failure of these trials. There are several factors-including the widespread adoption of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heart Failure
Share to Machine Learning
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precision Medicine

Share to Randomized Controlled Trials as Topic

Share to Research Design

Share to Stroke Volume

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 28681133
DOI: 10.1007/s12265-017-9759-8
PMCID: PMC5571647

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.PMID 28681133Read ↗

Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.Semantic proximity Read ↗

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials.Semantic proximity Read ↗

Large-scale multi-omics identifies drug targets for heart failure with reduced and preserved ejection fraction.Semantic proximity Read ↗

Towards Precision in HF Pharmacotherapy.Semantic proximity Read ↗

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Semantic proximity Read ↗

Effect of Beta Blockers on Exercise Capacity, Diastolic Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction: A Secondary Analysis of INDIE-HFpEF and RELAXSemantic proximity Read ↗

Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized TrialsSemantic proximity Read ↗

Towards precision medicine in heart failureSemantic proximity Read ↗

Drug Discovery and Development for Heart Failure Using Multi-Omics ApproachesSemantic proximity Read ↗

Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection Fraction.Semantic proximity Read ↗

Advancing Efficacy Prediction for EHR-based Emulated Trials in Repurposing Heart Failure TherapiesSemantic proximity Read ↗

Phenotype-guided approach for device-based therapies in heart failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.